Immix Biopharma (IMMX) to Release Quarterly Earnings on Thursday

Key Points

• Immix Biopharma (IMMX) will report Q1 2026 results after the market closes on Thursday, May 14, with analysts expecting earnings of ($0.145) per share and a conference call scheduled for May 15 at 4:00 PM ET.
• Analysts project about ($1) EPS for both the current and next fiscal year; the stock carries a consensus "Moderate Buy" rating (four Buys, one Hold, one Sell) with a consensus target of $18.25.
• Shares opened at $10.32 with a market cap near $547 million, a negative P/E, a 52-week range of $1.87–$11.61, and 50/200-day moving averages of $9.32/$6.60, respectively.

Immix Biopharma (NASDAQ:IMMX - Get Free Report) is expected to be issuing its Q1 2026 results after the market closes on Thursday, May 14th. Analysts expect the company to announce earnings of ($0.1450) per share for the quarter. Investors can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Friday, May 15, 2026 at 4:00 PM ET.

Immix Biopharma (NASDAQ:IMMX - Get Free Report) last issued its quarterly earnings data on Wednesday, March 25th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.12). On average, analysts expect Immix Biopharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Immix Biopharma Stock Performance

Shares of Immix Biopharma stock opened at $10.32 on Thursday. The stock has a market cap of $547.08 million, a P/E ratio of -11.60 and a beta of 0.12. The stock's fifty day moving average is $9.32 and its 200 day moving average is $6.60. Immix Biopharma has a one year low of $1.87 and a one year high of $11.61.

Wall Street Analyst Weigh In

A number of analysts have commented on IMMX shares. Morgan Stanley initiated coverage on Immix Biopharma in a research report on Wednesday, March 25th. They issued an "overweight" rating and a $20.00 price target for the company. Citizens Jmp reissued a "market outperform" rating and issued a $23.00 target price on shares of Immix Biopharma in a report on Friday, March 27th. HC Wainwright raised their target price on shares of Immix Biopharma from $12.00 to $15.00 and gave the stock a "buy" rating in a research note on Friday, March 27th. Wall Street Zen downgraded shares of Immix Biopharma from a "hold" rating to a "sell" rating in a report on Sunday, March 15th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Immix Biopharma in a research report on Tuesday, April 21st. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $18.25.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in IMMX. Virtu Financial LLC bought a new stake in shares of Immix Biopharma in the fourth quarter worth about $386,000. KVP Capital Advisors LP bought a new position in Immix Biopharma during the fourth quarter valued at approximately $1,205,000. XTX Topco Ltd boosted its stake in Immix Biopharma by 32.0% during the fourth quarter. XTX Topco Ltd now owns 46,394 shares of the company's stock valued at $243,000 after buying an additional 11,241 shares during the last quarter. Quadrature Capital Ltd purchased a new position in Immix Biopharma during the 4th quarter valued at approximately $116,000. Finally, Perceptive Advisors LLC bought a new stake in Immix Biopharma in the 4th quarter worth approximately $1,773,000. Hedge funds and other institutional investors own 11.26% of the company's stock.

About Immix Biopharma

Immix Biopharma NASDAQ: IMMX is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company's approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company's lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.